Phaseline

Companies › Arovella Therapeutics

Arovella Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALA-101
anti-CD19 CAR-T cell therapy
CD19Phase 1Non Hodgkin Lymphoma (NHL)Mar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07518329ALA-101Phase 1Non Hodgkin Lymphoma (NHL)OncologyMar 2030

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.